Second generation Absorbable Metal Stents (AMS)

ALVIMEDICA launched in 2007 and have the largest clean room in Europe at their facility in Istanbul, Turkey where they produce bare metal stents, drug-eluting stents and guiding, diagnostic, angiographic and balloon catheters.

The company have recently announced exciting results from their preclinical studies on the endothelialisation of CORACTO® their rapamycin (sirolimus) eluting stent, coated with PLGA, a completely bioabsorbable polymer. ALVIMEDICA say that their data shows that the bioabsorbable polymer degrades within two months.

The study conducted by Professor Renu Virmani used light and scanning microscopy to examine endothelial progression over 14 days versus a bare metal stent, CYPHER® stent and XIENCE V® stent. The trial was not powered for significance but results show that endothelial coverage of CORACTO at 14 days was better than that of both CYPHER and XIENCE V. As expected, the bare metal stent showed greatest endothelial coverage. CORACTO offers a platform with better deliverability, and the polymer avoids lifetime usage of antiplatelet therapy and reduces risks of thrombus formation, while maintaining an effective drug platform.

ALVIMEDICA have also conducted trials with Professor Reifart from Bad Suden in approximately 100 patients with CTO. The 24-month follow-up results show zero cases of stent thrombosis and little late loss.

CEO of ALVIMEDICA, Cem F. Bozkurt says: "We are delighted with the results of the study showing effective enothelialisation in animals and are very happy to be working with Professor Virmani on this study. We are equally pleased to be working with Professor Reifart on the CTO study and are confident that our product range will provide customers with what they need for successful intervention!"